Servicio de Microbiología, Hospital Ramón y Cajal and Instituto de Investigación Sanitaria (IRYCIS), Madrid, Spain.
J Clin Microbiol. 2014 Jan;52(1):122-9. doi: 10.1128/JCM.02340-13. Epub 2013 Oct 23.
Under the auspices of the Spanish Society for Infectious Diseases and Clinical Microbiology Quality Control program, 14 Escherichia coli strains masked as blood culture isolates were sent to 68 clinical microbiology laboratories for antimicrobial susceptibility testing to β-lactam antibiotics. This collection included three control strains (E. coli ATCC 25922, an IRT-2 producer, and a CMY-2 producer), six isogenic strains with or without the OmpF porin and expressing CTX-M β-lactamases (CTX-M-1, CTX-M-15, and CTX-M-14), one strain carrying a double mechanism for β-lactam resistance (i.e., carrying CTX-M-15 and OXA-1 enzymes), and four strains carrying CTX-M variants with different levels of resistance to β-lactams and β-lactam-β-lactamase inhibitor (BLBLI) combinations. The main objective of the study was to ascertain how these variants with reduced susceptibilities to BLBLIs are identified in clinical microbiology laboratories. CTX-M variants with high resistance to BLBLIs were mainly identified as inhibitor-resistant TEM (IRT) enzymes (68.0%); however, isogenic CTX-M mutant strains with reduced susceptibilities to BLBLIs and cephalosporins were mainly associated with extended-spectrum β-lactamase production alone (51 to 80%) or in combination with other mechanisms (14 to 31%). Concerning all β-lactams tested, the overall interpretative discrepancy rate was 11.5%, of which 38.1% were the consequence of postreading changes in the clinical categories when a resistance mechanism was inferred. Therefore, failure to recognize these complex phenotypes might contribute to an explanation of their apparent absence in the clinical setting and might lead to inadequate drug treatment selection. A proposal for improving recognition is to adhere strictly to the current CLSI or EUCAST guidelines for detecting reduced susceptibility to BLBLI combinations, without any interpretative modification.
在西班牙传染病和临床微生物学质量控制学会的主持下,将 14 株伪装成血培养分离株的大肠杆菌菌株分发给 68 家临床微生物学实验室进行β-内酰胺类抗生素的药敏试验。该研究包括 3 个对照菌株(E. coli ATCC 25922,IRT-2 产生菌和 CMY-2 产生菌),6 个具有或不具有 OmpF 孔蛋白且表达 CTX-M 型β-内酰胺酶的同基因菌株(CTX-M-1、CTX-M-15 和 CTX-M-14),1 株携带两种β-内酰胺类抗生素耐药机制的菌株(即携带 CTX-M-15 和 OXA-1 酶)和 4 株携带 CTX-M 变体的菌株,这些变体对β-内酰胺类抗生素和β-内酰胺类抗生素-β-内酰胺酶抑制剂(BLBLI)组合的耐药性水平不同。研究的主要目的是确定这些对 BLBLIs 耐药性降低的变体在临床微生物学实验室中是如何被识别的。对 BLBLIs 具有高耐药性的 CTX-M 变体主要被鉴定为抑制剂耐药型 TEM(IRT)酶(68.0%);然而,对 BLBLIs 和头孢菌素耐药性降低的同基因 CTX-M 突变菌株主要与单独产生超广谱β-内酰胺酶(51%至 80%)或与其他机制(14%至 31%)相关。对于所有测试的β-内酰胺类药物,总体解释性差异率为 11.5%,其中 38.1%是在推断耐药机制时临床类别发生读后变化的结果。因此,未能识别这些复杂表型可能是其在临床环境中明显缺失的原因之一,并可能导致药物治疗选择不当。提高识别能力的建议是严格遵循当前的 CLSI 或 EUCAST 指南,检测对 BLBLI 组合的耐药性降低,而无需进行任何解释性修改。